---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-026465"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T14:50:23.164767+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Director Julia Haller resigns from Outlook Therapeutics board, effective March 11, 2026

## Summary
- Dr. Julia Haller resigned as Class II director, also serving on Nominating and Corporate Governance Committee.
- Board accepted resignation on March 6, 2026, effective March 11, with board size reduced to nine.
- Resignation not due to any dispute with company; she cited new CEO duties at Wills Eye Hospital.
- Company thanked Dr. Haller for her contributions during her tenure.

## SEC filing metadata
- accession: 0001104659-26-026465
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926026465/0001104659-26-026465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926026465/tm268371d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-026465
- JSON: https://secwatch.observer/filing/0001104659-26-026465.json
- Plain text: https://secwatch.observer/filing/0001104659-26-026465.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.